PHASE I/II TRIAL OF CETRORELIX, AN ANTAGONIST OF LUTEINIZING HORMONE, FOR BPH

LH-RH拮抗剂的开放标签I/II期安全性和疗效研究 西曲瑞克治疗10例良性前列腺增生患者， 不适合行尿道切除术或拒绝经尿道切除术者。 本研究旨在研究安全性和 西曲瑞克（SB-75）治疗10例选定患者的疗效。 LH-RH拮抗剂西曲瑞克的治疗将持续两个月， 之后将停用拮抗剂。 停药后 在西曲瑞克治疗中，患者将每月随访一次， 三个月或直到症状增加到更大的水平 在治疗期间，症状减轻最大值的50%以上。

Open label phase I/II safety and efficacy study of LH-RH antagonist Cetrorelix, in 10 selected patients with benign prostatic hyperplasia who were unsuitable for prostatectomy or who refused transurethral resection. The study will be conducted in order to investigate the safety and efficacy of Cetrorelix (SB-75) therapy in 10 selected patients. Treatment with the LH-RH antagonist Cetrorelix will last for two months, after which the antagonist will be discontinued. After discontinuation of Cetrorelix therapy, patients will be followed on a monthly basis for three months or until the symptoms increase to a level which is greater than 50% of the maximum symptom reduction during the treatment period.